Pilaralisib
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
| Catalog Number | T2365 |
| Alternative Name(s) | SAR245408 , XL-147 |
| Research Area | PI3K/Akt/mTOR signaling |
| Molecular Formula | C25H25ClN6O4S |
| CAS# | 934526-89-3 |
| Purity | 98.24% |
| SMILES | C(=O)(C(C)(C)N)Nc1cc(ccc1)S(=O)(=O)Nc1nc2c(nc1Nc1c(ccc(c1)OC)Cl)cccc2 |
| Size | 100 mg |
| Supplier Page | https://www.targetmol.com/compound/Pilaralisib |
| Additional Information | https://www.targetmol.com/datasheet/T2365 |